Sitagliptin/Metformin Krka 50 mg/850 mg filmom obalené tablety Slóvakía - slóvakíska - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sitagliptin/metformin krka 50 mg/850 mg filmom obalené tablety

krka, d.d., novo mesto, slovinsko - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

SITAGAVIA MET 50 mg/1000 mg filmom obalené tablety Slóvakía - slóvakíska - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sitagavia met 50 mg/1000 mg filmom obalené tablety

krka, d.d., novo mesto, slovinsko - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

SITAGAVIA MET 50 mg/850 mg filmom obalené tablety Slóvakía - slóvakíska - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sitagavia met 50 mg/850 mg filmom obalené tablety

krka, d.d., novo mesto, slovinsko - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Eucreas Evrópusambandið - slóvakíska - EMA (European Medicines Agency)

eucreas

novartis europharm limited - vildagliptin, hydrochlorid metformín - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Icandra (previously Vildagliptin / metformin hydrochloride Novartis) Evrópusambandið - slóvakíska - EMA (European Medicines Agency)

icandra (previously vildagliptin / metformin hydrochloride novartis)

novartis europharm limited - vildagliptin, hydrochlorid metformín - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 a 5. 1 pre dostupné údaje o rôznych kombináciách).

Zomarist Evrópusambandið - slóvakíska - EMA (European Medicines Agency)

zomarist

novartis europharm limited  - vildagliptin, hydrochlorid metformín - diabetes mellitus, typ 2 - lieky používané pri cukrovke - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Vildagliptin / Metformin hydrochloride Accord Evrópusambandið - slóvakíska - EMA (European Medicines Agency)

vildagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, typ 2 - lieky používané pri cukrovke - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 a 5. 1 pre dostupné údaje o rôznych kombináciách).

Competact Evrópusambandið - slóvakíska - EMA (European Medicines Agency)

competact

cheplapharm arzneimittel gmbh - pioglitazone, hydrochlorid metformín - diabetes mellitus, typ 2 - lieky používané pri cukrovke - competact is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.